Mithra’s exclusivity on Estetrol applications extended to 2036 in Europe

Thanks to a new patent relating to Estetrol applications, Mithra secures its future results. A similar process is underway for the US market.

Liège, Belgique, 30 novembre 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted a new patent by the European Patent Office (EPO) relating to various pharmaceutical compositions containing Estetrol (E4) and their manufacturing process. In doing so, Mithra consolidates its exclusivity for the use of E4 in a wide range of indications such as the treatment of hormone-dependent cancers (breast and prostate in particular), dermatology, neuroprotection, dysmenorrhea and emergency contraception

 

Estetrol recognized as a “New Active Substance” by the European Medicines Agency (EMA)

This is the first time in more than 80 years that a new estrogen has been introduced in the field of contraception.

Liège, Belgium, 25 November 2020 – 7:30 CET – Mithra, a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that the European Medicines Agency (EMA) has designated Estetrol monohydrate (E4) as a New Active Substance (NAS) in its “Day 180” report, concluding the second phase of the ongoing evaluation of Estelle® birth control pills for the European market.

Creation of a New Share Option Plan in Replacement of the 2018 Share Option Plan

Liege, Belgium, 20 November 2020 – 17:45 CET – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that its board of directors has issued, within the framework of the authorized capital, a new share option plan for its personnel, covering 390,717 share options (the “2020 Share Option Plan”).

E4/DRSP, a Novel Combined Oral Contraceptive, submitted to Brazilian regulatory authorities

Liege, Belgium, 17 November 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the regulatory submission for E4/DRSP, a combined oral contraceptive containing estetrol (E4) and drospirenone (DRSP), has been submitted to the National Sanitary Surveillance Agency (ANVISA) by Mithra’s commercial partner, Libbs, the Women’s Health leader in Brazil.

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Venezuela

  • Mithra grants license to Chemical Dampe for commercialization of its vaginal contraceptive ring in Venezuela
  • Strengthening of the commercial presence in Latin and South America
  • Myring™ licenses granted to industry leaders in 36 countries, including the world’s three largest markets

Liege, Belgium, 10 November 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement (LSA) with Chemical Dampe for the commercialization of its hormonal contraceptive ring Myring™ in Venezuela. Based in Venezuela, Chemical Dampe builds alliances for the health of Venezuelans focused on women’s health with advanced technology and high quality products, made inside and outside its borders.

Mithra Renews its Board of Directors to Support its Operational Ambitions

Liege, Belgium, 3 November 2020, 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, on the initiative of its outgoing Chairman Marc Coucke,  its intention to renew its Board of Directors in accordance with its Strategic Operating Plan.